INSPIRE VETERINARY PARTNERS, INC. (IVPR): Nasdaq/NYSE listing notice — Inspire Veterinary Partners delisted from Nasdaq, now trades on OTCQB under IVPR

INSPIRE VETERINARY PARTNERS, INC.

Nasdaq denied Company's request to continue listing; common stock suspended from Nasdaq on Jan 21, 2026.
Common stock began trading on OTCQB Venture Market on Jan 21, 2026 under ticker IVPR.
CEO Kimball Carr cites focus on efficiency, unit-level operations, and margin improvement for 2026.
Company intends to continue SEC filings and prepare for online pet pharmacy launch in H1 2026.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

INSPIRE VETERINARY PARTNERS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 13, 2025, Inspire Veterinary Partners, Inc. (the “Company”) received a notice letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). The Notice stated that the Company’s securities would be suspended from trading on The Nasdaq Capital Ma

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

INSPIRE VETERINARY PARTNERS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-006203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.